Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Type: Form 8-K (Current Report)
Report Date: September 30, 2011
Event Date: September 30, 2011
Emergent BioSolutions Inc. reported the entry into a material definitive agreement via a contract modification with the Centers for Disease Control and Prevention (CDC). The agreement involves Emergent BioDefense Operations Lansing LLC, a wholly owned subsidiary of the Company.
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, margins, debt, or liquidity metrics. It discloses the potential financial value of a new contract award:
- Maximum Contract Value: Up to $1.25 billion (subject to availability of funding).
- Product Volume: Up to 44.75 million doses of BioThrax (Anthrax Vaccine Adsorbed).
- Contract Duration: Five years (September 30, 2011, through September 29, 2016).
Material Changes
The primary material change is the award of a new supply contract to replace the Company's current supply contract with the CDC. Delivery of doses under this new award is anticipated to commence in December 2011, immediately following the completion of deliveries under the existing contract.
Guidance, Outlook, and Risks
Outlook: The Company expects to begin fulfilling this contract in December 2011.
Contingencies: The maximum payment of $1.25 billion is explicitly subject to the availability of funding. The filing does not provide specific guidance on future earnings or operational risks beyond the funding contingency.
Investor Verification Checklist
- Verify the status of CDC funding availability for the $1.25 billion maximum contract value.
- Confirm the exact end date of the current supply contract to ensure seamless transition to the new award in December 2011.
- Review the specific pricing per dose implied by the $1.25 billion cap and 44.75 million dose volume.
- Monitor subsequent filings for actual revenue recognition as deliveries commence.